Page 21

AS LONG AS THEY FIGHT, WE FIGHT

Most pediatric lung transplant recipients develop chronic rejection within five years of transplant. Transplant patients undergo an immunosuppressive drug regimen, which helps prevent acute rejection but can lead to infections that may impact longer-term transplant outcomes. Rejection medication can impact the entire body, giving rise to high blood pressure, high cholesterol, arthritis and diabetes. In other words, the bodies of children with transplanted organs age quickly and never have a chance to bounce back. The next frontier of pediatric transplant research is already taking shape, thanks to funding from the CDI and the drive of its investigators to make life better for these children.

Photo: Fluorescence microscopic view of human lung fibroblasts

19

2017 Report to CDI Investors  
2017 Report to CDI Investors